A
Anne Schmitt-Hoffmann
Publications - 13
Citations - 1353
Anne Schmitt-Hoffmann is an academic researcher. The author has contributed to research in topics: Pharmacokinetics & Population. The author has an hindex of 11, co-authored 13 publications receiving 1144 citations.
Papers
More filters
Journal ArticleDOI
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
Johan Maertens,Issam I Raad,Kieren A. Marr,Thomas F. Patterson,Dimitrios P. Kontoyiannis,Oliver A. Cornely,Eric J. Bow,Galia Rahav,Dionysios Neofytos,Mickael Aoun,John W. Baddley,Michael Giladi,Werner J. Heinz,Raoul Herbrecht,William W. Hope,Meinolf Karthaus,Dong-Gun Lee,Olivier Lortholary,Vicki A. Morrison,Ilana Oren,Dominik Selleslag,Shmuel Shoham,George Richard Thompson,Misun Lee,Rochelle Maher,Anne Schmitt-Hoffmann,Bernhardt Zeiher,Andrew J. Ullmann +27 more
TL;DR: The results support the use of isavuconazole for the primary treatment of patients with invasive mould disease and non-inferiority was shown.
Journal ArticleDOI
Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy Volunteers
Anne Schmitt-Hoffmann,Brigitte Roos,Markus Heep,Michael Schleimer,Erhard Weidekamm,Tom Brown,Michael Roehrle,Christoph Beglinger +7 more
TL;DR: The pharmacokinetics of BAL8557 are well suited to maintaining concentrations of BAL4815 for a long period of time in the body and to enabling an effective treatment of systemic mycoses and based on the exposure data, oral bioavailability of BAL 4815 is assumed to be very high.
Journal ArticleDOI
Multiple-Dose Pharmacokinetics and Safety of the New Antifungal Triazole BAL4815 after Intravenous Infusion and Oral Administration of Its Prodrug, BAL8557, in Healthy Volunteers
Anne Schmitt-Hoffmann,Brigitte Roos,Jürgen Maares,Markus Heep,Jochen Spickerman,Erhard Weidekamm,Tom Brown,Michael Roehrle +7 more
TL;DR: Once-daily oral dosing of 50- or 100-mg equivalents of BAL8557 were recently demonstrated to be efficacious in a phase 2 study conducted with patients with esophageal candidiasis and will be further explored in the treatment of systemic mycoses.
Journal ArticleDOI
Safety and Pharmacokinetics of Isavuconazole as Antifungal Prophylaxis in Acute Myeloid Leukemia Patients with Neutropenia: Results of a Phase 2, Dose Escalation Study
TL;DR: The results of this analysis support the safety and tolerability of isavuconazole administered at 200 mg and 400 mg once-daily as prophylaxis in immunosuppressed patients at high risk of fungal infections.
Journal ArticleDOI
Single-Dose Pharmacokinetics and Safety of a Novel Broad-Spectrum Cephalosporin (BAL5788) in Healthy Volunteers
Anne Schmitt-Hoffmann,Brigitte Roos,Michael Schleimer,Jill Sauer,Anthony Man,Norman Nashed,Tom Brown,Antonio Perez,Erhard Weidekamm,Peter Kovacs +9 more
TL;DR: Results indicate that infusions of 750 mg twice a day should be adequate for the treatment of infections caused by MRSA.